The global antidepressant and Anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 213-page report you will receive 73 tables and 92 figures– all unavailable elsewhere.

The 213-page report provides clear detailed insight into the global antidepressant and anti-anxiety drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global antidepressant and anti-anxiety drugs market forecasts from 2019-2029

Our investigation shows forecasts to 2029 for the following submarket by drug class:

  • Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Atypical Antipsychotics
  • Tricyclic Antidepressants (TCAs)
  • Serotonin Antagonist and Reuptake Inhibitors (SARIs)
  • Benzodiazepines
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Others

Our investigation shows forecasts to 2029 for the following submarket by indication:

  • Major Depressive Disorder (MDD)
  • General Anxiety Disorder (GAD)
  • Panic Disorder (PD)
  • Obsessive Compulsive Disorder (OCD)
  • Others

Our investigation shows forecasts to 2029 for the selected leading drugs:

  • Abilify
  • Abilify Maintena
  • Brintellix/Trintellix
  • Cipralex/Lexapro
  • Cymbalta
  • Invega Sustenna/ Xeplion/Trinza/Trevicta
  • Lamictal
  • Rexulti
  • Risperdal Consta
  • Zyprexa

This report provides individual revenue forecasts to 2029 for these regional and national markets:

  • North America: the US, Canada
  • Europe: the UK, Germany, Spain, France, Italy, Russia, Rest of Europe
  • Asia-Pacific: Japan, China, India, South Korea, Rest of Asia-Pacific
  • RoW: Brazil, Mexico, Russia, South Africa, Rest of RoW

This report also provides discussion and qualitative analysis on:

  • Factors that drive and restrain the global antidepressant and Anti-anxiety drugs market.
  • Antidepressant drugs pipeline analysis
  • Anti-anxiety drugs pipeline analysis

This report discusses the selected leading companies:

  • Allergan plc.
  • AstraZeneca plc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Valeant Pharmaceuticals